Chromo Laboratories India is an API manufacturer based in India. It holds 88 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 7 February 2018 as VAI. Customs aggregates show $6.2M of exports covering 87 molecules to 20 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Sangareddy, India | 3008771562 |
| Molecule | Regulators | Docs |
|---|---|---|
| Omeprazole | US FDA | 4 |
| Rosuvastatin | US FDA | 4 |
| Zafirlukast | US FDA | 4 |
| Ziprasidone | US FDA | 4 |
| Moxifloxacin | SFDA (Saudi Arabia), US FDA | 3 |
| Abacavir | US FDA | 2 |
| Aripiprazole | US FDA | 2 |
| Armodafinil | US FDA | 2 |
| Atazanavir | US FDA | 2 |
| Atorvastatin | US FDA | 2 |
| Azilsartan Medoxomil | US FDA | 2 |
| Candesartan | US FDA | 2 |
| Chlorthalidone | US FDA | 2 |
| Darunavir | US FDA | 2 |
| Dexlansoprazole | US FDA | 2 |
| Dolutegravir | US FDA | 2 |
| Esomeprazole | US FDA | 2 |
| Ketorolac | US FDA | 2 |
| Lacosamide | US FDA | 2 |
| Lansoprazole | US FDA | 2 |
| Levocetirizine | US FDA | 2 |
| Levofloxacin | US FDA | 2 |
| Linezolid | US FDA | 2 |
| Modafinil | US FDA | 2 |
| Olanzapine | US FDA | 2 |
| Olmesartan | US FDA | 2 |
| Oseltamivir | US FDA | 2 |
| Posaconazole | US FDA | 2 |
| Praziquantel | US FDA | 2 |
| Pregabalin | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $1.6M | 9 |
| 2025 | Not reported | $6.2M | 20 |
| 2024 | Not reported | $6.9M | 21 |
| 2023 | Not reported | $4.0M | 22 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Chromo Laboratories India comes back tiered against every other supplier able to file there.
Start for free